Harbour Biomed and Yantai Lannacheng Biotechnology Co. Ltd. have entered into a long-term strategic collaboration to jointly advance the development of next-generation radionuclide-drug conjugates for the treatment of cancer.

Flagship Pioneering Inc. has announced a research program under its strategic collaboration with Pfizer Inc. for metastatic prostate cancer.

Rectify Pharmaceuticals Inc. has entered a strategic research and licensing agreement with Boehringer Ingelheim Pharma GmbH & Co. KG.